IL13 and infection: Administration of an anti-OX40L antibody during primary infection of neonatal mice resulted in reduced AHR, as well as reduced IL-5 and IL-13 levels in the bronchoalveolar lavage fluid (BALF) from mice when they were re-infected compared to mice treated with a control antibody [97].